Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Janusch BlautzikT Meindl

Abstract

Acetylcholinesterase inhibitors (AChEIs) are efficacious for the treatment of mild to moderate forms of Alzheimer's dementia (AD). Default-mode network (DMN) connectivity is considered to be early impaired in AD. Long-term effects of AChEIs on the DMN in AD have not yet been investigated. Twenty-eight AD patients and 11 age-matched healthy volunteers (HC) participated in the prospective study. AD patients were randomly assigned to either a pharmacotherapy arm (Galantamine, AD G) or to a placebo arm (AD P+G) for the period of 6 months followed by open-label Galantamine therapy from month 7-12. All subjects underwent neuropsychological testing, resting-state functional and structural MRI at baseline and after 12 months, AD patients additionally in between after 6 months. Thirteen AD patients completed the treatment trial and underwent all functional MRI follow-up sequences of good quality. Functional connectivity significantly increased within the AD G group in the posterior cingulate cortex and in the Precuneus between baseline and 12 months follow-up (pcorr<0.05). Between-group analyses demonstrated that functional connectivity in the AD G group significantly increased in the posterior cingulate cortex as well as in the Precune...Continue Reading

References

Jan 1, 1995·Alzheimer Disease and Associated Disorders·C Geula, M M Mesulam
Feb 24, 2001·Proceedings of the National Academy of Sciences of the United States of America·M E RaichleG L Shulman
Aug 23, 2001·Medical Image Analysis·M Jenkinson, S Smith
Dec 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Michael D GreiciusVinod Menon
Mar 4, 2003·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Larry TuneJohn M Hoffman
Aug 24, 2004·Molecular Pharmacology·Lifen ZhangJohn A Dani
Jun 15, 2005·Human Brain Mapping·Serge A R B RomboutsPhilip Scheltens
Apr 21, 2009·Neuron·William W SeeleyMichael D Greicius
Jun 10, 2009·Human Brain Mapping·Vesa KiviniemiOsmo Tervonen
Nov 20, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Angela R LairdPeter T Fox
Feb 24, 2010·Proceedings of the National Academy of Sciences of the United States of America·Bharat B BiswalMichael P Milham
Jul 27, 2010·Radiology·Hong-Ying ZhangGao-Jun Teng
Mar 29, 2011·Frontiers in Systems Neuroscience·Elena A AllenVince D Calhoun
Jun 16, 2011·Journal of Cognitive Neuroscience·Angela R LairdPeter T Fox
Feb 21, 2013·Journal of Clinical Psychopharmacology·Cristina Solé-PadullésJosé Luis Molinuevo
Nov 2, 2013·Current Neuropharmacology·Mirjana B ColovićVesna M Vasić
Feb 18, 2014·NeuroImage·Anderson M WinklerThomas E Nichols
Feb 25, 2014·Neuropsychology Review·Emily L Dennis, Paul M Thompson
Nov 26, 2014·Proceedings of the National Academy of Sciences of the United States of America·Alireza SalamiLars Nyberg

❮ Previous
Next ❯

Citations

May 2, 2018·Journal of Alzheimer's Disease : JAD·Teruyuki MatsuokaJin Narumoto
Apr 9, 2020·Frontiers in Pharmacology·Nurul Husna IbrahimJaya Kumar
May 5, 2017·Frontiers in Aging Neuroscience·Bernadet L KlaassensSerge A R B Rombouts
Nov 3, 2016·Current Opinion in Neurology·Michela PievaniGiovanni B Frisoni
Dec 31, 2020·Neuromodulation : Journal of the International Neuromodulation Society·Jordan LamDarrin J Lee
Mar 3, 2021·European Journal of Pharmacology·Tayebeh NooriSamira Shirooie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.